Panbela Provides Business Update and Reports Q3 2023 Financial Results
November 09, 2023 16:10 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
November 03, 2023 07:55 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
November 02, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D. MINNEAPOLIS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Panbela...
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
October 31, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
October 25, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
October 24, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
September 26, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical...
Panbela to Present at the LD Micro Investor Conference
September 19, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
September 05, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023 08:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...